314 related articles for article (PubMed ID: 34328096)
1. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
Miao G; Sun X
Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
[TBL] [Abstract][Full Text] [Related]
2. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
3. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
4. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Dangaj D; Lanitis E; Zhao A; Joshi S; Cheng Y; Sandaltzopoulos R; Ra HJ; Danet-Desnoyers G; Powell DJ; Scholler N
Cancer Res; 2013 Aug; 73(15):4820-9. PubMed ID: 23722540
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.
Leung J; St-Onge P; Stagg J; Suh WK
Cancer Immunol Immunother; 2017 Apr; 66(4):491-502. PubMed ID: 28074226
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers.
Song X; Zhou Z; Li H; Xue Y; Lu X; Bahar I; Kepp O; Hung MC; Kroemer G; Wan Y
Cancer Discov; 2020 Dec; 10(12):1872-1893. PubMed ID: 32938586
[TBL] [Abstract][Full Text] [Related]
7. The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer.
Hu X; Liu Y; Zhang X; Kong D; Kong J; Zhao D; Guo Y; Sun L; Chu L; Liu S; Hou X; Ren F; Zhao Y; Lu C; Zhai D; Yuan X
Neoplasia; 2020 Nov; 22(11):539-553. PubMed ID: 32966956
[TBL] [Abstract][Full Text] [Related]
8. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8
Li J; Lee Y; Li Y; Jiang Y; Lu H; Zang W; Zhao X; Liu L; Chen Y; Tan H; Yang Z; Zhang MQ; Mak TW; Ni L; Dong C
Immunity; 2018 Apr; 48(4):773-786.e5. PubMed ID: 29625896
[TBL] [Abstract][Full Text] [Related]
9. Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.
Iizuka A; Kondou R; Nonomura C; Ashizawa T; Ohshima K; Kusuhara M; Isaka M; Ohde Y; Yamaguchi K; Akiyama Y
Oncol Rep; 2016 Nov; 36(5):2625-2632. PubMed ID: 27632942
[TBL] [Abstract][Full Text] [Related]
10. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
[TBL] [Abstract][Full Text] [Related]
11. B7-H4 reduces the infiltration of CD8+T cells and induces their anti-tumor dysfunction in gliomas.
Qi Y; Hu L; Ji C; Yang X; Yao J; Chen D; Yao Y
Neoplasia; 2024 Aug; 54():101007. PubMed ID: 38796932
[TBL] [Abstract][Full Text] [Related]
12. Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration.
Li L; Nian S; Liu Q; Zhang B; Jimu W; Li C; Huang Z; Hu Q; Huang Y; Yuan Q
Int Immunopharmacol; 2024 May; 132():111926. PubMed ID: 38552297
[TBL] [Abstract][Full Text] [Related]
13. B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.
Rahbar R; Lin A; Ghazarian M; Yau HL; Paramathas S; Lang PA; Schildknecht A; Elford AR; Garcia-Batres C; Martin B; Berman HK; Leong WL; McCready DR; Reedijk M; Done SJ; Miller N; Youngson B; Suh WK; Mak TW; Ohashi PS
Cancer Immunol Res; 2015 Feb; 3(2):184-95. PubMed ID: 25527357
[TBL] [Abstract][Full Text] [Related]
14. Generation of avian-derived anti-B7-H4 antibodies exerts a blockade effect on the immunosuppressive response.
Lin TY; Tsai TH; Chen CT; Yang TW; Chang FL; Lo YN; Chung TS; Cheng MH; Chen WC; Tsai KC; Lee YC
Exp Anim; 2021 Aug; 70(3):333-343. PubMed ID: 33716253
[TBL] [Abstract][Full Text] [Related]
15. Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model.
Leung J; Suh WK
J Immunol; 2013 Jun; 190(12):6651-61. PubMed ID: 23686485
[TBL] [Abstract][Full Text] [Related]
16. Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against
Yuan X; Liu Y; Li G; Lan Z; Ma M; Li H; Kong J; Sun J; Hou G; Hou X; Ma Y; Ren F; Zhou F; Gao S
Cancer Immunol Res; 2019 Sep; 7(9):1440-1456. PubMed ID: 31350278
[TBL] [Abstract][Full Text] [Related]
17. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target.
MacGregor HL; Ohashi PS
Clin Cancer Res; 2017 Jun; 23(12):2934-2941. PubMed ID: 28325750
[TBL] [Abstract][Full Text] [Related]
19. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
[TBL] [Abstract][Full Text] [Related]
20. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]